LEXINGTON, Mass., Jan. 9, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President and COO.

- AGEN1223 is a novel bi-specific designed to selectively deplete regulatory T cells in the tumor microenvironment - First patient dosed; combinations with other IO agents planned for 2020 LEXINGTON, Mass., Jan. 8, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with

LEXINGTON, Mass., Dec. 19, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in

LEXINGTON, Mass., Nov. 12, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced that it will host an R&D Day on November 15, 2019.

- UroGen receives rights to zalifrelimab to be used in its proprietary sustained release formulation for patients with high-grade non-muscle invasive bladder cancer LEXINGTON, Mass., Nov. 11, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of

- PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies clear INDs & advance into clinical trials - NexGen CTLA-4 (AGEN1181) advances to 3rd cohort;

LEXINGTON, Mass., Oct. 31, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019.

LEXINGTON, Mass., Sept. 30, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced today that Jennifer Buell, PhD, Chief Operating Officer of Agenus, present an

FDA acceptance of IND filing for AGEN1223; triggers cash milestone AGEN1223 is a first-in-class bi-specific designed to deplete regulatory T cells in tumor microenvironment LEXINGTON, Mass., August 28, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a

Invented by Agenus, licensed to Gilead, GS-1423 is a bi-functional antibody designed to block tumor escape mechanisms Supply supports ongoing Phase 1 of GS-1423 in patients with advanced solid tumors LEXINGTON, Mass., August 21, 2019 / PRNewswire / -- Agenus Inc.